| P50 | author | Kerstin Uvnäs-Moberg | Q4984130 |
| | Mats B. Humble | Q42858790 |
| P2093 | author name string | Susanne Bejerot | |
| | Ingemar Engström | |
| P2860 | cites work | Oxytocin: the great facilitator of life. | Q24651638 |
| | Neuromodulation by oxytocin and vasopressin | Q27027986 |
| | The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability | Q28272890 |
| | Obsessive-compulsive disorder: a review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V | Q28275558 |
| | Oxytocin--anatomy and functional assignments: a minireview | Q28296410 |
| | Neuroanatomical and cellular substrates of hypergrooming induced by microinjection of oxytocin in central nucleus of amygdala, an experimental model of compulsive behavior | Q28576750 |
| | Modulating social behavior with oxytocin: how does it work? What does it mean? | Q28730932 |
| | A New Depression Scale Designed to be Sensitive to Change | Q29614720 |
| | Problems with measuring peripheral oxytocin: can the data on oxytocin and human behavior be trusted? | Q30624507 |
| | Reactivity of serotonin in whole blood: relationship with drug response in obsessive-compulsive disorder. | Q32144286 |
| | Different antipsychotics elicit different effects on magnocellular oxytocinergic and vasopressinergic neurons as revealed by Fos immunohistochemistry | Q33506130 |
| | Possible role of neuropeptides in obsessive compulsive disorder | Q33546754 |
| | Oxytocin and Major Depressive Disorder: Experimental and Clinical Evidence for Links to Aetiology and Possible Treatment | Q33664227 |
| | Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin | Q33881046 |
| | Obsessions and compulsions in Asperger syndrome and high-functioning autism | Q33987477 |
| | Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication | Q34374925 |
| | Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators | Q34404992 |
| | Effects of 5-HT agonists, selective for different receptor subtypes, on oxytocin, CCK, gastrin and somatostatin plasma levels in the rat. | Q34415847 |
| | Dendritic peptide release and peptide-dependent behaviours | Q34486938 |
| | Oxytocin, vasopressin, and autism: is there a connection? | Q34491655 |
| | Pharmacotherapies in the management of obsessive-compulsive disorder | Q34547177 |
| | Oxytocin and the neural mechanisms regulating social cognition and affiliative behavior | Q34608356 |
| | Oxytocin during the initial stages of romantic attachment: relations to couples' interactive reciprocity | Q34635419 |
| | Effects of selective serotonin reuptake inhibitor treatment on plasma oxytocin and cortisol in major depressive disorder | Q34694131 |
| | Evaluation of enzyme immunoassay and radioimmunoassay methods for the measurement of plasma oxytocin | Q35054947 |
| | Serotonin, panic disorder and agoraphobia: short-term and long-term efficacy of citalopram in panic disorders | Q35516040 |
| | Effects of intranasal oxytocin and vasopressin on cooperative behavior and associated brain activity in men. | Q35653107 |
| | Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder | Q36374340 |
| | Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines | Q36407113 |
| | Updated overview of the putative role of the serotoninergic system in obsessive-compulsive disorder | Q36703810 |
| | Abnormal corticostriatal-limbic functional connectivity in obsessive-compulsive disorder during reward processing and resting-state | Q37217144 |
| | Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine | Q37919724 |
| | The role of central oxytocin in obsessive compulsive disorder and related normal behavior | Q40649973 |
| | A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder | Q40986710 |
| | Oxytocin in obsessive compulsive disorder | Q41107666 |
| | Obsessive-compulsive disorder and serotonin: is there a connection? | Q41243764 |
| | Increased plasma levels of oxytocin in response to afferent electrical stimulation of the sciatic and vagal nerves and in response to touch and pinch in anaesthetized rats | Q42515035 |
| | Oxytocin may mediate the benefits of positive social interaction and emotions | Q43070504 |
| | Obsessive-compulsive disorder with poor insight: a three-year prospective study. | Q43218552 |
| | Oxytocin and carbetocin effects on spontaneous behavior of male rats: modulation by oxytocin receptor antagonists. | Q43255293 |
| | Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol | Q43291314 |
| | Chemical coding of GABA(B) receptor-immunoreactive neurones in hypothalamic regions regulating body weight | Q44282886 |
| | Obsessive compulsive behaviour in autism--towards an autistic-obsessive compulsive syndrome? | Q44315647 |
| | Serotonin receptors involved in vasopressin and oxytocin secretion | Q44316695 |
| | Repeated intranasal oxytocin administration in early life dysregulates the HPA axis and alters social behavior. | Q44521779 |
| | Evoked axonal oxytocin release in the central amygdala attenuates fear response | Q44740042 |
| | Low CSF oxytocin reflects high intent in suicide attempters | Q44881125 |
| | Long-term fluoxetine treatment decreases 5-HT1A receptor responsivity in obsessive-compulsive disorder | Q45731485 |
| | Evidence that oxytocin exerts anxiolytic effects via oxytocin receptor expressed in serotonergic neurons in mice | Q46116537 |
| | Comorbid obsessive-compulsive personality disorder in obsessive-compulsive disorder (OCD): a marker of severity | Q46900422 |
| | Vasopressin, oxytocin, corticotrophin-releasing factor, and sodium responses during fluoxetine administration in the rat. | Q47835221 |
| | Stimulation of 5-HT1A and 5-HT2/5-HT1C receptors induce oxytocin release in the male rat. | Q48283716 |
| | The interface of oxytocin-labeled cells and serotonin transporter-containing fibers in the primate hypothalamus: a substrate for SSRIs therapeutic effects? | Q48398177 |
| | Oxytocin in postnatally depressed mothers: its influence on mood and expressed emotion | Q48592196 |
| | Localization of high-affinity binding sites for oxytocin and vasopressin in the human brain. An autoradiographic study | Q48675360 |
| | Central and peripheral release of oxytocin following chronic homotypic stress in rats | Q48713745 |
| | MDMA-induced c-Fos expression in oxytocin-containing neurons is blocked by pretreatment with the 5-HT-1A receptor antagonist WAY 100635. | Q49064161 |
| | An autistic dimension: a proposed subtype of obsessive-compulsive disorder | Q50301404 |
| | Autistic traits in obsessive-compulsive disorder | Q50310162 |
| | MDMA enhances "mind reading" of positive emotions and impairs "mind reading" of negative emotions. | Q50592804 |
| | Interaction of 5-HTTLPR and a variation on the oxytocin receptor gene influences negative emotionality. | Q50652337 |
| | Symptom structure of antipsychotic-induced obsessive compulsive symptoms in schizophrenia patients. | Q50756773 |
| | Anxiety, cortisol, and attachment predict plasma oxytocin. | Q50906454 |
| | Serum oxytocin levels in patients with depression and the effects of gender and antidepressant treatment. | Q51616268 |
| | Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse. | Q51899385 |
| | The changing prevalence and severity of obsessive-compulsive disorder criteria from DSM-III to DSM-IV. | Q51930597 |
| | Changes in Cerebrospinal Fluid Neurochemistry During Treatment of Obsessive-compulsive Disorder With Clomipramine | Q52023318 |
| | Elevated cerebrospinal fluid levels of oxytocin in obsessive-compulsive disorder. Comparison with Tourette's syndrome and healthy controls. | Q52023320 |
| | Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder | Q52046635 |
| | Intranasal oxytocin in obsessive-compulsive disorder. | Q52134259 |
| | Urinary oxytocin and social bonding in related and unrelated wild chimpanzees. | Q52837322 |
| | Obsessive-compulsive disorder | Q56910158 |
| | Amperozide and clozapine but not haloperidol or raclopride increase the secretion of oxytocin in rats | Q67527076 |
| | Clomipramine in obsessive-compulsive disorder | Q68544978 |
| | Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline | Q70254897 |
| | Intranasal oxytocin in obsessive-compulsive disorder | Q71702441 |
| | Long-term fluoxetine, but not desipramine, inhibits the ACTH and oxytocin responses to the 5-HT1A agonist, 8-OH-DPAT, in male rats | Q72269253 |
| | Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects | Q72621882 |
| | Oxytocin as a possible mediator of SSRI-induced antidepressant effects | Q74672046 |
| | Normal CSF oxytocin and NPY levels in OCD | Q77322587 |
| | Factors associated with major depressive disorder occurring after the onset of obsessive-compulsive disorder | Q79556713 |
| | Evidence-based pharmacotherapy of obsessive-compulsive disorder | Q80792006 |
| | Clomipramine and initial worsening in panic disorder: beyond the 'jitteriness syndrome' | Q83364954 |
| P921 | main subject | oxytocin | Q169960 |
| | placebo | Q269829 |
| P304 | page(s) | 344 | |
| P577 | publication date | 2013-12-23 | |
| P1433 | published in | BMC Psychiatry | Q15750257 |
| P1476 | title | Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study | |
| P478 | volume | 13 | |